Literature DB >> 25135909

Quantitative effect of natural killer-cell licensing on hepatocellular carcinoma recurrence after curative hepatectomy.

Naoki Tanimine1, Yuka Tanaka1, Tsuyoshi Kobayashi1, Hirotaka Tashiro1, Daiki Miki2, Michio Imamura3, Hiroshi Aikata3, Junko Tanaka4, Kazuaki Chayama5, Hideki Ohdan6.   

Abstract

Natural killer (NK) cells have a potential role in immune surveillance of hepatocellular carcinoma (HCC). Self-recognition of human leukocyte antigens (HLA) through killer immunoglobulin-like receptors (KIR) confers competence to NK cells-a process termed "licensing." We investigated the effect of NK-cell licensing on the susceptibility of patients to HCC recurrence. A total of 170 Japanese patients with HCC who underwent primary curative hepatectomy between 1996 and 2010 were enrolled in this study. The median follow-up period was 5.4 years. We analyzed their KIR-HLA genotypes with sequence-specific polymorphism-based typing and estimated their susceptibility to HCC recurrence by performing propensity score-matching analyses. The presence of KIR2DL1-C2, KIR2DL2-C1, KIR3DL1-BW4, or KIR3DL2-A3/11, functional compound genotypes that intrinsically license NK cells, did not markedly affect HCC recurrence. However, the multiplicity of those compound KIR-HLA genotypes was significantly associated with the HCC recurrence rate, i.e., the cumulative risk of recurrence in patients with at least three compound genotypes was significantly lower than that in patients with one or two compound genotypes, suggesting that the effect of NK-cell licensing on HCC recurrence is quantitative. Patients at high risk of HCC recurrence after curative hepatectomy could be identified by KIR-HLA genotyping. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25135909     DOI: 10.1158/2326-6066.CIR-14-0091

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  6 in total

Review 1.  Cancer treatment and the KIR-HLA system: an overview.

Authors:  Patrizia Leone; Valli De Re; Angelo Vacca; Franco Dammacco; Vito Racanelli
Journal:  Clin Exp Med       Date:  2017-02-10       Impact factor: 3.984

Review 2.  Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.

Authors:  Min Yu; Zonghai Li
Journal:  Front Med       Date:  2017-08-05       Impact factor: 4.592

3.  Impact of multiplicity of functional KIR-HLA compound genotypes on hepatocellular carcinoma.

Authors:  Naoki Tanimine; Hideki Ohdan
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

4.  Deficiency of the adaptor protein SLy1 results in a natural killer cell ribosomopathy affecting tumor clearance.

Authors:  Saeed Arefanian; Daniel Schäll; Stephanie Chang; Reza Ghasemi; Ryuji Higashikubo; Alex Zheleznyak; Yizhan Guo; Jinsheng Yu; Hosseinali Asgharian; Wenjun Li; Andrew E Gelman; Daniel Kreisel; Anthony R French; Hani Zaher; Beatrice Plougastel-Douglas; Leonard Maggi; Wayne Yokoyama; Sandra Beer-Hammer; Alexander S Krupnick
Journal:  Oncoimmunology       Date:  2016-09-27       Impact factor: 8.110

Review 5.  Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications.

Authors:  Pil Soo Sung; Jeong Won Jang
Journal:  Int J Mol Sci       Date:  2018-11-19       Impact factor: 5.923

6.  Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma.

Authors:  Masahiro Ohira; Ryuichi Hotta; Yuka Tanaka; Toshiharu Matsuura; Akin Tekin; Gennaro Selvaggi; Rodrigo Vianna; Camillo Ricordi; Phillip Ruiz; Seigo Nishida; Andreas G Tzakis; Hideki Ohdan
Journal:  Cancer Immunol Immunother       Date:  2021-07-19       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.